De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.

Hacohen Y, Androdias G, Arrambide G, Bruijstens AL, Ciccarelli O, Cobo-Calvo A, Flanagan EP, Kim HJ, Iacobaeus E, Lünemann JD, Stankoff B, Tintore M, Marignier R

Open source

DOI
10.1212/wnl.0000000000218482
Published
2026 Sep 22
Container
Neurology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1212/wnl.0000000000218482,
  title = {De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.},
  author = {Hacohen Y and Androdias G and Arrambide G and Bruijstens AL and Ciccarelli O and Cobo-Calvo A and Flanagan EP and Kim HJ and Iacobaeus E and Lünemann JD and Stankoff B and Tintore M and Marignier R},
  year = {2026},
  journal = {Neurology},
  doi = {10.1212/wnl.0000000000218482},
  url = {https://doi.org/10.1212/wnl.0000000000218482}
}

RIS

TY  - JOUR
TI  - De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.
AU  - Hacohen Y
AU  - Androdias G
AU  - Arrambide G
AU  - Bruijstens AL
AU  - Ciccarelli O
AU  - Cobo-Calvo A
AU  - Flanagan EP
AU  - Kim HJ
AU  - Iacobaeus E
AU  - Lünemann JD
AU  - Stankoff B
AU  - Tintore M
AU  - Marignier R
PY  - 2026
JO  - Neurology
DO  - 10.1212/wnl.0000000000218482
UR  - https://doi.org/10.1212/wnl.0000000000218482
ER  - 

APA

Y, H., G, A., G, A., AL, B., O, C., A, C., EP, F., HJ, K., E, I., JD, L., B, S., M, T., & R, M. (2026). De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.. Neurology. https://doi.org/10.1212/wnl.0000000000218482

Source records